BNGO:NSD-Bionano Genomics, Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 0.60

Change

+0.01 (+1.44)%

Market Cap

USD 0.09B

Volume

4.02M

Average Target Price

USD 1.44 (+139.58%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-29 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

+0.04 (+0.01%)

USD44.71B 61.31 36.64
DXCM DexCom, Inc

+1.99 (+0.50%)

USD38.32B 173.65 108.43
IDXX IDEXX Laboratories, Inc

-1.31 (-0.34%)

USD32.86B 69.09 46.81
EXAS Exact Sciences Corporation

+2.31 (+2.32%)

USD14.97B N/A N/A
GH Guardant Health, Inc

+2.25 (+2.06%)

USD10.84B N/A N/A
ICLR ICON Public Limited Company

+2.67 (+1.44%)

USD9.79B 29.89 20.21
QDEL Quidel Corporation

+16.36 (+8.24%)

USD8.84B 55.27 34.27
PRAH PRA Health Sciences, Inc

-0.87 (-0.88%)

USD6.34B 29.56 17.69
NTRA Natera, Inc

+2.62 (+3.74%)

USD5.89B N/A N/A
SYNH Syneos Health, Inc

-0.42 (-0.79%)

USD5.55B 28.65 16.75

ETFs Containing BNGO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -51.61% 12% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.61% 10% F 9% F
Trailing 12 Months  
Capital Gain -11.76% 36% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.76% 34% F 39% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -39.69% N/A N/A 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.69% N/A N/A 2% F
Risk Return Profile  
Volatility (Standard Deviation) 40.44% N/A N/A 31% F
Risk Adjusted Return -98.16% N/A N/A 4% F
Market Capitalization 0.09B 31% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 14.61 16% F 8% F
Price / Cash Flow Ratio -2.90 51% F 69% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -1,464.01% 2% F 1% F
Return on Invested Capital -120.82% 19% F 7% F
Return on Assets -71.65% 8% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.61 85% B 82% B-
Short Percent 3.76% 59% F 47% F
Beta 1.67 26% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector